trending Market Intelligence /marketintelligence/en/news-insights/trending/VmjpKh7RFv5WXPG-c8DvBg2 content esgSubNav
In This List

Pfizer's arthritis drug gets favorable vote from FDA panel

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond


Pfizer's arthritis drug gets favorable vote from FDA panel

Pfizer Inc. said the U.S. Food and Drug Administration's Arthritis Advisory Committee voted 10 to 1 to recommend approval of Xeljanz to treat adults with active psoriatic arthritis.

The company's supplemental new drug application for the indication is under review by the FDA, with a decision expected by December.

Xeljanz is currently approved to treat adults with moderately to severely active rheumatoid arthritis.